Business UpdateSep 8, 2026, 08:26 AM
Veru Inc. Advances Sabizabulin for Pancreatic Cancer; Discontinues Inflammation Program
AI Summary
Veru Inc. announced a strategic shift in its drug development pipeline, deciding to advance its oral agent sabizabulin for the treatment of metastatic pancreatic cancer that has become resistant to daraxonrasib. This decision follows new, positive preclinical data demonstrating sabizabulin's augmented anticancer activity in resistant cell lines. Consequently, the company will discontinue its exploration of sabizabulin for chronic inflammation. Veru also provided an update on its enobosarm obesity program, confirming it is on track with an interim analysis for the Phase 2b PLATEAU trial expected in Q1 2027.
Key Highlights
- Veru Inc. will advance sabizabulin for metastatic pancreatic cancer resistant to daraxonrasib based on new preclinical data.
- The company will no longer pursue sabizabulin for chronic inflammation related to atherosclerotic cardiovascular disease.
- New preclinical data shows sabizabulin has potent anticancer activity (IC50=18.2nM) in daraxonrasib-resistant pancreatic cancer cell lines.
- Sabizabulin demonstrated collateral sensitivity in daraxonrasib-resistant pancreatic and colon cancer cell lines.
- Previous Phase 1b/2 study in prostate cancer showed promising efficacy and a good safety profile for sabizabulin.
- Veru Inc. plans to seek regulatory clarity from the FDA for a planned Phase 2b clinical trial in Q4 2026.
- Enobosarm obesity program is on track with Phase 2b PLATEAU clinical trial interim analysis expected in Q1 2027.
Price Impact
More from VERU